June 2, 2022 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS).
New PIMSH 12: COVID-19 Vaccination Quality Measure
On Monday, June 6, 2022, users will see the new 2022 CMS-approved Practice Insights QCDR custom MIPS Quality Measure, PIMSH12: COVID-19 Vaccinations.
In partnership with US Oncology Network clinicians and the Ontada Clinical Review Board, our team developed this new QCDR measure to assist practices in tracking their patients’ COVID-19 vaccination status. Specifically, this measure assesses the completeness of a full COVID-19 vaccination series.
Alongside the clinical benefits of tracking vaccination status, new quality measures in their first year of reporting have a 7-point benchmark floor. Groups and clinicians that meet the 70% data completeness and the case minimum requirements would be eligible to receive at least 7 points for reporting this measure for the performance year 2022.
Additionally, reporting the new PIMSH 12 measure for 2022 will help to establish future measure benchmarks and promote the value of our custom QCDR measures to CMS.
It is important to note that this measure’s focus is to assess the completeness of a full COVID-19 vaccination series. Currently, PIMSH 12 does not assess the status of boosters. Future development may incorporate booster status to provide additional insight into patient care.
Status of Dashboard Updates for 2022
CMS releases updates to the quality measure specifications annually for the MIPS program and bi-annually for the OCM program. These measure specifications have been reviewed and Practice Insights is currently working on the required technical updates to align with the revised requirements. McKesson will continue to notify practices once measures have been updated based on the current 2022 requirements. The measures listed below either have no 2022 update required or have been updated.
| Measure | Description |
|---|---|
MIPS Quality Measures Dashboard |
|
| #047 | Advance Care Plan |
| #110 | Preventive Care and Screening: Influenza Immunization |
| #128 | Body Mass Index (BMI) Screening and Follow-Up Plan |
| #130 | Current Medications Documentation |
| #134 | Depression Screening |
| #143 | Pain Intensity Quantified |
| #144 | Pain Care Plan |
| #226 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| #374 | Closing the Referral Loop |
| #451 | RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy |
| #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| #457 | Patients Admitted to Hospice for < 3 Days |
| PIMSH#1 | Advance Care Planning in Metastatic Cancer |
| PIMSH#2 | Utilization of GCSF in Metastatic Colon/Rectal Cancer (Inverse Measure) |
| PIMSH#4 | Patient-Reported Pain Improvement |
| PIMSH#9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH#10 | Hepatitis B Serology Testing for Prophylactic Treatment Prior to Receiving Anti CD20 Targeting Drugs |
| PIMSH#12 | COVID-19 Vaccinations |
OCM Performance Measures Dashboard 1H 2022 |
|
| OCM 4A | Pain Intensity Quantified |
| OCM 4B | Plan of Care for Pain |
| OCM5 | Depression Screening |